Biologic

WASHINGTON — In this video from the American Academy of Orthopaedic Surgeons Next Generation of Biologics Symposium, Shane A. Shapiro, MD, spoke about the need to standardize biologic therapies for musculoskeletal conditions.

WASHINGTON — Jason L. Dragoo, MD, FAAOS, spoke about the next generation of orthobiologics at the American Association of Orthopaedic Surgeons Next Generation of Biologics Symposium, here.

WASHINGTON — At the American Academy of Orthopaedic Surgeons Next Generation of Biologics Symposium, Scott Rodeo, MD, FAAOS, spoke about a clinical study that used gene-modified human umbilical vein endothelial cells in rotator cuff repair.

Healio spoke with Philip J. Mease, MD, about ongoing research in psoriatic arthritis.

WASHINGTON — Male and female patients experienced similar improvements in their severe, uncontrolled asthma with tezepelumab over a 52-week period, according to data presented at the American Thoracic Society International Conference.

CHICAGO — An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023.

WASHINGTON — A debate at the American Thoracic Society International Conference changed some minds about whether providers could or should combine and overlap biologic treatments to treat severe asthma.

WASHINGTON — Patients with asthma experienced fast and substantial reductions in fractional exhaled nitric oxide with the SAR443765 bifunctional NANOBODY molecule, which blocks thymic stromal lymphopoietin and IL-13, according to a study.

WASHINGTON — Tezepelumab reduced annualized asthma exacerbation rates compared with placebo among patients with severe, uncontrolled asthma regardless of prior omalizumab use, according to study results.

Black patients and those on Medicaid had lower rates of adherence to biologics prescribed for asthma, often due to patient-level barriers, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.